Cytek Biosciences, Inc. (CTKB) - 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Cytek Biosciences, Inc. for the fiscal year ended December 31, 2024. Cytek is a leading cell analysis solutions company utilizing Full Spectrum Profiling (FSP) technology to distinguish fluorescent tags on single cells. The company operates globally with manufacturing facilities in the U.S., China, and Singapore. In 2023, Cytek acquired the Flow Cytometry and Imaging (FCI) business from Luminex Corporation, expanding its portfolio to include Amnis and Guava-branded instruments.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $200.5 million | $193.0 million | +4% |
| Net Loss | $(6.0) million | $(12.1) million | Improvement |
| Gross Profit | $111.1 million | $109.4 million | +2% |
| Gross Margin | 55% | 57% | -200 bps |
| Operating Cash Flow | $25.4 million | $5.3 million | Significant Increase |
| Cash & Investments | $277.9 million | $262.7 million | +6% |
| Long-Term Debt | $1.1 million | $1.6 million | Decrease |
Note: Revenue growth was driven by a 30% increase in service revenue, partially offset by a 2% decline in product revenue. The reduction in net loss was primarily due to a $7.3 million non-cash reduction in a legal settlement liability related to a Becton, Dickinson and Company (BD) agreement.
Material Changes vs. Prior Period
- Revenue Mix Shift: Service revenue grew significantly ($47.2M vs $36.3M) due to an expanding installed base and instruments coming off warranty, while product revenue declined slightly due to lower average selling prices and reduced contribution from FCI products.
- Margin Compression: Gross margin decreased to 55% from 57%, driven by higher material costs, less favorable instrument product mix, and higher production overhead.
- Expense Management: Research and Development (R&D) expenses decreased by 11% to $39.4 million due to streamlined efforts. Sales and Marketing expenses remained flat at $49.1 million following a commercial team reorganization.
- Share Repurchases: The company repurchased 3.97 million shares for approximately $21.6 million in 2024 under a $50 million program that expired at year-end. A new $50 million program was approved in December 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management expects to continue investing in commercial infrastructure and R&D. The company aims to drive recurring revenue through consumable pull-through from its growing installed base and expand into clinical markets, particularly in the U.S. where products are currently Research Use Only (RUO).
Unusual Items: The 2024 financial results were significantly impacted by a $7.3 million reduction in the legal settlement liability with BD, recorded as a benefit to interest income/expense. This was due to a revision of long-term forecasted net sales subject to royalties.
Key Risks:
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding the control environment, general IT controls (access security and change management), and journal entry review procedures. Deloitte issued an adverse opinion on internal controls.
- Supply Chain: Reliance on single or sole-source suppliers for key components (lasers, semiconductors) poses a risk of production disruption.
- Regulatory & Trade: New U.S. export license requirements announced in January 2025 for high-parameter flow cytometers to certain countries (including China) may impact sales. Additionally, new tariffs on imports from China, Mexico, and Canada could increase costs.
- Legal Proceedings: Beckman Coulter filed a patent infringement lawsuit in August 2024 regarding Cytek's Aurora and Northern Lights products. Trial is scheduled for August 2026.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for the identified material weaknesses in internal controls and IT systems.
- Export Control Impact: Assess the potential revenue impact of the new U.S. export license requirements for China and other jurisdictions announced in early 2025.
- Legal Settlement Liability: Review the assumptions used for the BD royalty forecast and the sustainability of the $7.3 million benefit recorded in 2024.
- Patent Litigation: Monitor the status of the Beckman Coulter infringement lawsuit and potential counterclaims.
- Service Revenue Sustainability: Confirm the growth trajectory of service revenue as a percentage of total revenue to validate the recurring revenue model.